{"schema_version":"secwatch.filing_event.v1","accession":"0001127537-22-000003","form_type":"8-K","ticker":"LUNG","cik":"0001127537","company_name":"Pulmonx Corp","filed_at":"2022-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.489869+00:00","generated_at":"2026-06-27T05:17:34.281769+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pulmonx Q4 revenue $13.7M (+39% YoY); FY rev $48.4M (+48%); guides FY22 $55-60M","bullets":["Q4 net loss $13.0M ($0.35/sh) vs $9.3M ($0.27/sh) YoY; FY net loss $48.7M ($1.35/sh) vs $32.2M ($3.16/sh).","Q4 gross margin 74.8% (vs 72.0% YoY); FY gross margin 73.6% (vs 64.8%); improvement from production efficiencies.","U.S. treatment centers for Zephyr Valves expanded to 214, a 45% increase since start of 2021.","FY 2022 revenue guidance $55-60M; Q1 2022 revenue expected $9-10M due to COVID impact.","Regulatory submission for Zephyr Valve approval in Japan made in December 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001127537-22-000003","json":"https://secwatch.observer/filing/0001127537-22-000003.json","markdown":"https://secwatch.observer/filing/0001127537-22-000003.md","text":"https://secwatch.observer/filing/0001127537-22-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1127537/000112753722000003/0001127537-22-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1127537/000112753722000003/lung-20220223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T05:17:34.281769+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}